Bellerophon Therapeutics, Inc.
BLPH · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $5 | $8 | $82 | $9 |
| - Cash | $4 | $11 | $15 | $7 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | -$2 | $67 | $2 |
| Revenue | $0 | $0 | $6 | $0 |
| % Growth | – | -100% | – | – |
| Gross Profit | $0 | -$0 | $6 | -$0 |
| % Margin | – | – | 100% | – |
| EBITDA | -$2 | -$5 | $1 | -$5 |
| % Margin | – | – | 26.2% | – |
| Net Income | -$2 | -$5 | $3 | -$7 |
| % Margin | – | – | 50% | – |
| EPS Diluted | -0.16 | -0.42 | 0.27 | -0.78 |
| % Growth | 61.9% | -255.6% | 134.6% | – |
| Operating Cash Flow | -$6 | -$5 | $3 | -$4 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$6 | -$5 | $3 | -$4 |